Patent application number | Description | Published |
20090107903 | Anticoagulant-coated dipstick for use with a blood centrifuge rotor - An anticoagulant-coated dipstick is selectively receivable by the central fill port of a rotor of a blood centrifuge. The dipstick includes an elongated, rod-like member having a first axial end and an opposite second axial end, and a cap affixed to the second axial end. At least a portion of a surface of the rod-like member is coated with an anticoagulant. The elongated rod-like member of the dipstick is dimensioned in length and diameter to be receivable through the central fill port of the rotor to contact a blood sample contained therein. The cap is circular in shape, with a diameter that is greater than that of the rotor fill port to entirely cover and seal the fill port to prevent leakage therethrough of a blood sample contained in the rotor, especially when the rotor is gently agitated or inverted. | 04-30-2009 |
20100254854 | CHEMICAL ANALYZER - A chemical analyzer includes a slide transport mechanism having a slide track adapted to hold a plurality of reagent test slides, a sample metering device, an incubator formed as a part of the slide transport mechanism to precisely maintain the temperature of the reagent test slides, a slide ejector mechanism to remove the slides from the slide transport mechanism, a sample preparation station, which includes a centrifuge, and associated electronics and software. The slide transport mechanism holds a plurality of trapezoidally-shaped reagent test slides about its circumference, which slides are loaded onto the transport mechanism by the slide inserter mechanism. The slide transport mechanism positions the reagent test slides under the sample metering device, which device deposits a predetermined volume of sample onto each slide. The slide transport mechanism also carries the slides above a reflectometer. After testing has been completed, the slide ejector mechanism automatically removes the reagent test slides from the slide transport mechanism. | 10-07-2010 |
Patent application number | Description | Published |
20100250331 | EVALUATING THE QUALITY OF WEB-BASED PROPERTIES - Methods, systems, and media are provided for evaluating the quality of web-based properties for use as hosts of advertisements. Properties are automatically and dynamically evaluated for appropriateness of content, for instance, based upon extracted keywords and/or contextual information categories. Upon submission of an advertisement request, properties determined to be of insufficient quality are served a neutral advertisement, served a message indicating that no advertisement will be served, or served nothing at all. Advertisements determined upon submission of an advertisement request to be of sufficient quality are served one or more non-neutral advertisements as requested. | 09-30-2010 |
20110314007 | METHODS, SYSTEMS, AND MEDIA FOR CONTENT RANKING USING REAL-TIME DATA - Methods, systems, and media for content ranking using real-time data are provided. In accordance with some embodiments of the present invention, a method, implemented on a processor, for ranking content is provided. The method can include, among other things: receiving real-time information from a plurality of sources; supplementing the received real-time information with historical information and user influence information; analyzing the supplemented real-time information from the plurality of sources to determine real-time trend information; receiving a plurality of content snippets from a content provider; detecting similarities between each of the plurality of content snippets and the determined real-time trend information; ranking the plurality of content snippets based on the detected similarities; and displaying the ranked plurality of content snippets. | 12-22-2011 |
Patent application number | Description | Published |
20130315819 | POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF AS A DRUG TARGET FOR PRODUCING DRUGS AND BIOLOGICS - This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against KIAA0746, CD20 or CD55 antigens, which are differentially expressed in cancer and in specific blood cells, and diagnostic and therapeutic usages. This invention further relates to the discovery of extracellular domains of KIAA0746 and its variants, CD20 and its variants, CD55 and its variants, which are suitable targets for immunotherapy, cancer therapy, treatment of inflammatory, allergic and autoimmune disorders, and drug development. | 11-28-2013 |
20140220011 | POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF AS A DRUG TARGET FOR PRODUCING DRUGS AND BIOLOGICS - This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, ClORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and ClORF32 and its variants which are suitable targets for immunotherapy, cancer therapy, and drug development. | 08-07-2014 |
20140255389 | POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF AS A DRUG TARGET FOR PRODUCING DRUGS AND BIOLOGICS - This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and C1ORF32 and its variants which are suitable targets for immunotherapy, cancer therapy, and drug development. | 09-11-2014 |
20140255411 | POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF AS A DRUG TARGET FOR PRODUCING DRUGS AND BIOLOGICS - This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and C1ORF32 and its variants a which are suitable targets for immunotherapy, cancer therapy, and drug development. | 09-11-2014 |
20140294765 | LSR ANTIBODIES, AND USES THEREOF FOR TREATMENT OF CANCER - This invention relates to antibodies and antigen binding fragments and conjugates containing same, and/or alternative scaffolds, specific for LSR molecules, which are suitable drugs for immunotherapy and treatment of specific cancer. | 10-02-2014 |
20140363446 | POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF AS A DRUG TARGET FOR PRODUCING DRUGS AND BIOLOGICS - This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and C1ORF32 and its variants awhich are suitable targets for immunotherapy, cancer therapy, and drug development. | 12-11-2014 |
Patent application number | Description | Published |
20100184839 | ALLELIC POLYMORPHISM ASSOCIATED WITH DIABETES - The invention relates to the identification of allelic polymorphism in a diabetes associated gene, particularly in a gene encoding phosphofructokinase (PFK) and use thereof for diagnosing diabetes predisposition and state and for predicting the response to a therapeutic agent. | 07-22-2010 |
20110052501 | POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF AS A DRUG TARGET FOR PRODUCING DRUGS AND BIOLOGICS - This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against KIAA0746, CD20 or CD55 antigens, which are differentially expressed in cancer and in specific blood cells, and diagnostic and therapeutic usages. This invention further relates to the discovery of extracellular domains of KIAA0746 and its variants, CD20 and its variants, CD55 and its variants, which are suitable targets for immunotherapy, cancer therapy, treatment of inflammatory, allergic and autoimmune disorders, and drug development. | 03-03-2011 |
20120134997 | POLYPEPTIDES AND POLYNUCLEOTIDES, AND USES THEREOF AS A DRUG TARGET FOR PRODUCING DRUGS AND BIOLOGICS - This invention relates to a novel target for production of immune and non-immune based therapeutics and for disease diagnosis. More particularly, the invention provides therapeutic antibodies against VSIG1, ILDR1, LOC253012, AI216611, C1ORF32 or FXYD3 antigens, which are predicted co-stimulatory family members and which are differentially expressed in cancers including, lung cancer, ovarian cancer, and colon cancer, and diagnostic and therapeutic usages. The use of these antibodies for modulating B7 costimulation and related therapies such as the treatment of autoimmunity are also provided. This invention further relates to the discovery of extracellular domains of VSIG1 and its variants, FXYD3 and its variants, ILDR1 and its variants, LOC253012 and its variants, AI216611 and its variants, and C1ORF32 and its variants which are suitable targets for immunotherapy, cancer therapy, and drug development. | 05-31-2012 |